- AU$757.22m
- AU$681.01m
- AU$0.03m
Brief: Artrya Submits 510(K) Application To US FDA
Australia's Artrya falls as FY loss widens
Brief: Artrya Ltd Says Loss For Year Attributable A$14 Mln
Brief: Artrya On Track For FDA Application Submission Following Second Q-Submission Meeting
Brief: Artrya Announces Five Year Strategic Agreement With Cone Health
Brief: Artrya Enters Commercial Agreement With Cardiac Centre NSW And Cardiac CT Centre NSW
Artrya hits over 3-week high on first commercial agreement in Australia
Brief: Artrya Announces Strategic Agreement With US Hospital Group Tanner Health System & Healthliant Ventures
Brief: Artrya Ltd Says Loss For Half-Year Attributable A$6.9 Million
Brief: Artrya Ltd Says Confident To See First Revenue In FY2024
Brief: Artrya Enters US Market With Five-Year Strategic Commercial Partnership Agreement
Brief: Artrya Posts FY Net Loss Attributable A$11.2 Mln
Founder John Barrington Am
Brief: Artrya Posts HY Net Loss For Period Attributable A$6.5 Million
Brief: Artrya Successful In Gaining European Regulatory Approval
Brief: Artrya Says FY Net Loss Attributable A$17.2 Million
Brief: Artrya Says Announces First U.S. Clinical Partnership With Huntsville Heart Center
Brief: Artrya Says It Opens U.S. Operations In Los Angeles
Australian medical tech firm Artrya rises on formation of U.S. unit